Pre-B-cell leukemia homeobox 1 (PBX1) shows functional and possible genetic association with bone mineral density variation

Ching-Lung Cheung¹, Benjamin Y.Y. Chan¹, Vivian Chan¹, Shiro Ikegawa⁵, Ikuyo Kou⁵, Heidi Ngai¹, David Smith², Keith D.K. Luk³, Qing-Yang Huang¹, Seijiro Mori⁶, Pak-Chung Sham⁴ and Annie W.C. Kung¹,*

¹Department of Medicine, ²Department of Biochemistry and ³Department of Orthopaedics and Traumatology, ⁴Genome Research Centre, The University of Hong Kong, Pokfulam, Hong Kong, Republic of China, ⁵Laboratory for Bone and Joint Disease, Center for Genomic Medicine, RIKEN, Tokyo, Japan and ⁶Department of Internal Medicine, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan

Received August 13, 2008; Revised and Accepted November 19, 2008

Bone mineral density (BMD) is one of the major determinants of risk for osteoporotic fracture. Multiple studies reveal that peak bone mass is under strong genetic influence. One of the major susceptibility loci for peak spine BMD has been mapped to chromosome 1q21–q23 in the Caucasian population. We have previously replicated this finding in Southern Chinese pedigrees and detected a maximum multipoint log of odds (LOD) score of 2.36 in this region. To further fine-map this region, 380 single-nucleotide polymorphic (SNP) markers were genotyped in 610 sibpairs from 231 families. Several markers were identified in the association analysis as important candidates underlying BMD variation. Among them, successful replication was demonstrated for SNPs in pre-B-cell leukemia homeobox 1 (PBX1) gene in two other unrelated case–control cohorts. The functional role of PBX1 in bone metabolism was examined in vitro using human bone-derived cells (HBDC) and murine MC3T3-E1 pre-osteoblasts. PBX1 mRNA was constitutively expressed in both HBDC and MC3T3-E1 cells. Immunostaining revealed that PBX1 is localized in the nucleus compartment. Silencing of PBX1 by RNAi in MC3T3-E1 cells decreased the expression of Runx2 and Osterix, the critical transcription factors for osteogenesis, but accelerated cell proliferation and bone nodule formation. Overall, our data suggest a genetic and functional association of PBX1 with BMD.

INTRODUCTION

Osteoporosis (MIM 166710) is a major public health problem that is associated with excess disability and mortality and a huge socioeconomic burden due to its complication of bone fractures. It is characterized by low bone mass and microarchitectural deterioration of bone tissue that lead to increased bone fragility and a consequent increased fracture risk (1). As the world’s population ages, the prevalence rate of osteoporosis and osteoporotic fractures increase in parallel with approximately 200 million women worldwide suffer from osteoporosis. Vertebral compression fractures lead to pain, deformity and disability whereas hip fractures associated with falls result in loss of mobility and, in some cases, death. Bone strength is predominantly determined by bone mineral density (BMD) and bone quality (2). BMD predicts fracture risk independently, and clinically it is the best characterized bone parameter that can be precisely measured (1).

Numerous studies have demonstrated that BMD has a strong genetic component (3–6). Up to 85% of the variability of BMD in young Caucasian adults is attributable to genetic factors. Similar studies conducted in Chinese pedigrees also reveal a heritability estimate of 0.73 for spine BMD in women, a figure that remains significant after adjustment for anthropometric measurements and lifestyle factors (7).
Despite numerous attempts made over previous decades to identify gene(s) involved in osteoporosis, the complex genetic architecture of osteoporosis remains ambiguous, and the genes responsible for BMD variation are largely unknown. The recent development of high throughput technology that allows genotyping of hundreds of thousands of SNPs across the genome has enabled unbiased genome-wide association (GWA) studies to be performed.

Over the past few years, a number of genome-wide linkage scans have searched for genes that underlie BMD variation and several susceptibility loci have been identified (8–11). Among these, chromosome 1q shows the strongest linkage signal with spine BMD; the highest LOD score of 4.3 is observed in the region of 175.62–182.35 cM (11,12). In genome-wide linkage scans in mice, a LOD score as high as 14.02 was observed in its homologous region of human chromosome 1q21–31 (13). This observation has, nonetheless, not been confirmed by other genome-wide linkage scans. We recently performed a collaborative meta-analysis of nine genome-wide scans for BMD that involved 11,842 subjects and detected the strongest evidence of linkage at chromosome 1q shows the strongest linkage at chromosome 1q21–31 (13). This observation has, nonetheless, not been confirmed by other genome-wide linkage scans. We recently performed a collaborative meta-analysis of nine genome-wide scans for BMD that involved 11,842 subjects and detected the strongest evidence of linkage at chromosome 1q shows the strongest linkage at chromosome 1q21–31 (13).

In this present study, fine-mapping of the quantitative trait loci (QTL) in this 6 Mb region was performed using 380 SNPs. Spine BMD association was localized to the region of 1p13.3–q23.3 (P = 0.002) (14). Similarly, our linkage study in 306 Southern Chinese pedigrees revealed a linkage peak region of ~10 cM between 165.62 and 191.52 cM with spine BMD, with the maximum multipoint LOD score of 2.36 (15).

In this present study, fine-mapping of the quantitative trait loci (QTL) in this 6 Mb region was performed using 380 SNPs. Spine BMD association was localized to the region of 1p13.3–q23.3 (P = 0.002) (14). Similarly, our linkage study in 306 Southern Chinese pedigrees revealed a linkage peak region of ~10 cM between 165.62 and 191.52 cM with spine BMD, with the maximum multipoint LOD score of 2.36 (15).

**RESULTS**

**Initial genetic screening**

We genotyped 380 tagging SNPs across a 6 Mb region on chromosome 1q. Among these 380 SNPs, the quality control criteria of a genotyping call rate >90%, MAF >0.05, duplicate error rate <0.02 and Hardy–Weinberg equilibrium (HWE) P > 0.01 were achieved for 262 SNPs (Supplementary Material, Table S3). The linkage disequilibrium (LD) pattern in terms of r² and D' of these 262 SNPs is summarized in Supplementary Material, Figure S2. Using a BMD spine z-score as the phenotype, eight SNPs showed a significant total association at the empirical P-value of 0.05 through 10,000 permutations. Only two SNPs, i.e. rs2800791 and rs9661977 in the PBX1 gene, showed consistent associations in the within-association tests (Table 1). All association results (including insignificant results) are provided in Supplementary Material, Table S4. Imputation of untyped SNP genotypes using the Markov Chain framework implemented in Markov Chain Haplotyping software (MaCH) (16) did not improve the association signal (Data not shown).

<table>
<thead>
<tr>
<th>SNP</th>
<th>Gene</th>
<th>Physical position</th>
<th>Within association</th>
<th>Total association</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Beta Emp. P*</td>
<td>Beta Emp. P*</td>
</tr>
<tr>
<td>rs2800791</td>
<td>PBX1</td>
<td>162830048</td>
<td>0.210 0.038</td>
<td>0.270 0.004</td>
</tr>
<tr>
<td>rs9661977</td>
<td>PBX1</td>
<td>163016317</td>
<td>0.290 0.032</td>
<td>0.240 0.050</td>
</tr>
</tbody>
</table>

*Significance was defined by an empirical P-value of <0.05 as derived from 10,000 permutations.

**Replication in two large case–control cohorts**

Replication in the Chinese case–control population was achieved with rs2800791. Logistic regression analysis revealed a P-value of 0.007 for rs2800791 and 0.4 for rs9661977 (Table 2). Replication in the Japanese cohort showed a P-value of 0.05 for rs2800791 and 0.344 for rs9661977. The meta-analyses showed a pooled odds ratio (OR) of 0.83 (95% CI: 0.73–0.94; P = 0.003) and 0.94 (95% CI: 0.77–1.15; P = 0.285) for rs2800791 and rs9661977, respectively.

**Resequencing of PBX1 in 20 high- and 20 low-spine BMD subjects**

To determine whether rs2800791 could be in LD with another functional SNP, we resequenced genomic DNA for all exons, 5'–UTR and 3'–UTR from 20 high-spine BMD subjects who carried the protective allele at rs2800791 and 20 low-spine BMD subjects who carried the at risk allele at rs2800791. This resequencing effort identified two novel polymorphisms in the 5'–UTR −776G/C and −668C/A, and one known nonsynonymous SNP rs2275558 in exon 2. Genotyping these three SNPs in 835 southern Chinese case–control subjects revealed an extremely low-allele frequency of the 5'–UTR SNPs (MAF < 0.01) and no association between rs2275558 and spine BMD variation (P = 0.93; OR = 1.02; 95% CI, 0.69–1.51).

**Functionality of PBX1 in osteoblasts**

Semi-quantitative PCR revealed that PBX1 mRNA expression was consistently present in both HBDCs and MC3T3 mouse pre-osteoblast cells during proliferation and differentiation phases (Fig. 1A and B). PBX1 protein was localized in the nuclei compartment but not in the cytoplasm (Fig. 1C and D). The expression of PBX1 mRNA in MC3T3 cells was suppressed 3.7-fold by 100 ng/ml of BMP2 after 4 days of culture (Fig. 1E), while estradiol, PTH and dexamethasone had no effect on PBX1 gene expression. As rs2800791 lies in intron 2 and that intronic sequence variation might affect mRNA splicing, we studied the mRNA species from HBDC of subjects with different rs2800791 genotypes but did not observe any variation in mRNA species.

Transient silencing of PBX1 gene with RNAi in MC3T3-E1 pre-osteoblast cells for 4 days was confirmed by real-time PCR and western blot analysis (Supplementary Material, Fig. S3A and B). Transient knock-down of PBX1 increased the cell proliferation rate by 30% compared with control.
Nonetheless, the gene expression of Runx2 and Osterix, the two master factors that control osteoblast differentiation, was downregulated at Day 4 post-transfection by 3- and 2-fold, respectively (Fig. 2B). Interestingly, matrix mineralization was advanced and mineralized bone nodules were seen at Day 20 after transient knock-down of PBX1 compared with Day 25 in controls. By Day 30, enhanced mineralization in the PBX1 knock-down cells was observed (scramble control: 100 ± 3%; RNAi 153 ± 15%, \( P < 0.001 \), Fig. 2C). These results provide evidence that PBX1 is involved at different stages of osteoblast proliferation and differentiation.

**DISCUSSION**

This association and replication study identified PBX1 as a possible osteoporosis susceptibility gene for spine BMD. According to the HapMap data, Rel 21a/phase II Jan 07, NCBI B36 assembly, rs2800791 of PBX1 is located in an LD block flanked by rs12739548 and rs12405060 in intron 2. This LD block is present in both Chinese and Japanese populations (Supplementary Material, Fig. S4). It is postulated that either rs2800791 itself or the SNP in high LD is the functional variant accounting for the association with BMD variation. We sequenced the exons and immediate intron–exon boundaries in both homozygous CC and TT carriers of rs2800791 and did not identify any novel sequence variants in homozygous carriers of the variant T alleles with high BMD. Since rs2800791 is located in intron 2, we determined whether the sequence variation might affect mRNA splicing, but we failed to detect variation in mRNA species in subjects with different rs2800791 genotypes. Next, we used TFSearch (TFSEARCH: Searching Transcription Factor Binding Sites, http://mbs.cbrc.jp/research/db/TFSEARCH.html) set at default settings to search for potential alteration in transcription factor binding site. Interestingly, the c-myc-binding site was present in the sequence with T allele but not C allele of rs2800791 with a score of 85.6. C-myc is a proto-oncogene that functions as a transcription factor. Activation is induced by estrogen through the recruitment of estrogen receptors, such as estrogen receptor alpha (ESR1), and specific coactivators to their promoters (17). As a recent study showed that c-myc is an effector of estrogen/estrogen receptor signaling, we, therefore, further investigated the epistasis between ESR1, estrogen receptor beta (ESR2) and PBX1 using multi-factor dimensionality reduction (MDR) (18). The MDR revealed significant epistasis between the promoter SNP T-1213C of ESR2 and rs2800791 in PBX1 with a testing balanced accuracy of 0.553 (Supplementary Material, Table S5). The putative PBX1-binding site was also investigated in a 2 kb sequence upstream of the first exon of ESR1 and ESR2 using JASPAR database (19). Three predicted putative PBX1-binding sites were present within a 2 kb region of ESR1, but not ESR2 (Supplementary Material, Table S6). Estrogen and estrogen receptors are well-known mediators in bone metabolism (20), and the relationship underlying estrogen and PBX1 and probably c-myc requires further elucidation. To investigate the possible functional role of rs2800791, we retrieved the expression data from the study (\( P < 0.01 \), Fig. 2A).
of Stranger et al. (21). Using HapMap CHB+JPT lymphoblastoid cell lines to perform the genotype-expression correlation using linear regression method with adjustment of ethnicity, the genotype rs2800791 (denoted as additive fashion) was not correlated with PBX1 expression. We believe that this nonsignificant correlation does not necessarily negate the possible association of rs2800791 with PBX1 expression as the number of subjects in the HapMap project is small. Thus, future experiment and replication are needed to validate our findings.

Figure 1. PBX1 mRNA was consistently expressed in human bone-derived cells (HBDC) (A) and murine MC3T3-E1 pre-osteoblast cells (B). PBX1, pre-B-cell leukemia homeobox 1; col1a1, collagen type 1α1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase. Immunofluorescence staining HBDCs showing PBX1 (green) in the nucleus and coll1a1 (red) in the cytoplasm (C), with mice sera as negative control (D). Effect of PTH (10^{-10} M), Dexamethasone (10^{-6} M), 17β-estradiol (10^{-6} M) and BMP2 (100 ng/ml) on PBX1 mRNA expression (E). Results are expressed as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001 (versus Day 0); aP < 0.05; bP < 0.01; cP < 0.001 (versus control).
Two 300K GWA studies were recently published (22,23). In one of these studies of over 10,000 Caucasian subjects using Illumina humanHap 300 chips, several BMD candidate genes, RANKL, OPG and ESR1, and two novel findings near the major histocompatibility complex and zinc finger and BTB domain containing 40 gene showed association with BMD variation at genome-wide significant level (22). In this GWA study, 52 SNPs were genotyped in \textit{PBX1} gene locus.

![Graph A](image1.png)

**Figure 2.** Transient knock-down of \textit{PBX1} significantly enhanced cell proliferation of murine MC3T3-E1 pre-osteoblasts compared with scramble RNAi control (A). The two master genes controlling osteoblast differentiation, \textit{Runx2} and \textit{Osterix}, were significantly downregulated by \textit{PBX1} knock-down (B). Enhanced matrix mineralization was observed at Day 30 by Von-Kossa silver stain (C). Results are expressed as mean ± SD. *\textit{P} < 0.05; **\textit{P} < 0.01; ***\textit{P} < 0.001 (versus Day 0); *\textit{P} < 0.05; **\textit{P} < 0.01; ***\textit{P} < 0.001 (versus control).
and 14 showed P-value of <0.05 (27%), although rs9661977 and rs2800791 were polymorphic in Caucasian subjects with MAF of 0.273 and 0.4, respectively, neither of them were included in this GWA study. None of the 52 SNPs were in high LD with rs9661977 ($r^2 > 0.8$) based on the LD pattern in Chinese and Japanese populations. Interestingly, the SNP rs2800783, which was in high LD ($r^2 = 0.846$) but different haplotype block with rs2800791, showed a trend toward significant association with spine BMD ($P = 0.062$). The G allele of rs2800783 is associated with a lower risk of low BMD (U. Styrkarsdottir, personal communication), and this is in the same direction of association as the T allele of rs2800791 observed in our study. This further suggest the functional importance of rs2800791 or SNPs in high LD.

We showed in this study that PBX1 is constitutively expressed in both HBDC and mouse pre-osteoblast cells. PBX1 gene expression is downregulated by BMP2 during the proliferative phase of the pre-osteoblasts in culture. Transient gene silencing of PBX1 in pre-osteoblasts led to enhanced cell proliferation and suppression of the activation of Runx2 and Osterix gene expression, the two indispensable factors required for commitment and development of skeletal lineage cells (24,25). The accelerated proliferation and increased cell number was associated with advanced matrix mineralization and enhanced bone nodule formation. These results suggested that PBX1 is likely acting as a negative regulator for osteoblast proliferation, and also plays a role in terminal differentiation. Indeed, these results are consistent with the previous observation that PBX1 is required in skeletal patterning and programming. PBX1 homozygous knockout mice showed several defects in organogenesis and differentiation, including skeletogenesis and chondrocyte differentiation (26). PBX1 $^{-/-}$ embryos had thinning, compressions and fusions of the vertebral bodies and neural arches. Defects in proximal but not distal forelimbs and hindlimbs were also observed. PBX1 $^{-/-}$ mice also had precocious expression of Colla1, a marker of bone formation, and accelerated endochondral ossification. PBX1 is thus likely important in developmental programs and plays a role in coordinating the extent and/or timing of chondrocyte and osteoblast proliferation and terminal differentiation. The present in vitro observations together with our genetic association data with spine BMD strongly suggest that the PBX1 gene is important in bone metabolism.

Our pilot study has identified PBX1 as a novel susceptibility gene for osteoporosis. First, we used informative sib-pairs from the original linkage cohort to identify the susceptibility gene underlying the peak to enhance the chance of identifying the QTL gene. Secondly, successful replications in two independent case–control cohorts further support the association of PBX1 with BMD variation. Finally, we determined the functional role of PBX1 in osteoblast biology with in vitro cellular studies. There were, nonetheless, several limitations to this study. There exists the possibility that our BMD association data are a false positive finding. Although two cohorts with different designs were used for replication, more replication is necessary to confirm these findings. The replication data in the Japanese population were of marginal significance. This Japanese case–control cohort comprised of subjects with high and low BMD at either hip or spine, and based on the evidence that genetic control of BMD is site specific (27), it is likely that this cohort is less powerful than the Chinese cohort that comprised of only high- and low-spine BMD subjects. Recent studies suggest sex-specific (28) and menopausal-specific (29) effects for candidate genes underlying BMD variation, but we did not perform sub-group analysis for this study as the original linkage signal was observed in the whole population, not any sub-group (15). For the in vitro study, only transient knock-down experiments were done and further stable gene-silencing studies are necessary to unravel the mechanisms whereby PBX1 affects bone biology.

To summarize, the advantage of our powerful and robust study design ensured a greater chance of identifying the candidate genes in chromosome 1q. Our pilot study that used high-density SNPs on chromosome 1q QTL has narrowed down the list of candidate genes to PBX1. The consistent associations between rs2800791 in PBX1 and BMD variation in almost 3000 subjects, including both sib-pair-based and case–control-based cohorts, together with the expression of PBX1 in human bone cells and the data obtained from in vitro PBX1 knockdown analysis, suggest that PBX1 is a novel susceptibility gene for osteoporosis and in osteoblastogenesis. Further replication study and extensive characterization of the mechanisms of PBX1 and its variant alleles in BMD variation may aid the development of new management strategies for patients with osteoporosis.

**MATERIAL AND METHODS**

**Study population**

All study subjects were drawn from the expanding database being compiled at the Osteoporosis Centre at Queen Mary Hospital, the University of Hong Kong, for the study of genetics and environmental determinants of osteoporosis in Southern Chinese. Subjects were invited to attend the Osteoporosis Center for BMD assessment. Those with BMD Z-score of $-1.3$ or less at either the lumbar spine L1–4 or at the femoral neck (equivalent to the lowest 10th percentile of the population) were defined as proband, and their family members were also invited for the study. A detailed description of subject ascertainment, inclusion and exclusion criteria has been described previously (30). In the previous chromosome 1q linkage study, a total of 306 families with 1459 individuals (293 males and 1166 females) were analyzed (15). These pedigrees contained 1260 sib-pairs, 143 cousin pairs, 2356 parent–child pairs, 522 grandparent–grandchild pairs and 512 avuncular pairs.

To fine-map the region for BMD variation in chromosome 1q, we adopted a new approach to select the most informative sib-pairs based on both phenotype and identity-by-descent (IBD) information. The IBD information at chromosome 1q, we adopted a new approach to select the most informative sib-pairs based on both phenotype and identity-by-descent (IBD) information. The IBD information at chromosome 1q between all 1260 sib-pairs was obtained from the MERLIN program using the microsatellite data from the linkage study. This selection procedure ensured the retention of most association information for a smaller number of subjects submitted for further genotyping. Using the Genetic Power Calculator (http://pngu.mgh.harvard.edu/~purcell/gpc/), the non-centrality parameter (NCP) of an overall (between and within sib-ship) association test, for all 1260 sib-pairs, was
estimated to be 255 (assuming a QTL that contributes 10% of the phenotypic variance and perfect LD with QTL and marker). A software described elsewhere (Kwan et al., submitted) was used to rank the sib-pairs for information content, given their phenotypes and IBD sharing; genotyping the most informative 610, 464 and 355 sib-pairs retained approximately 90, 80 and 70% of the total (NCP) (Supplementary Material, Fig. S1). The most informative 610 sib-pairs (Supplementary Material, Table S1) were subsequently selected and genotyped using high-density SNP markers in order to retain 90% of the total NCP from the entire sample.

For the second screening and replication, we adopted a case–control design with subjects selected from the opposite extremes of the distribution of BMD trait values. Although cumbersome, replication of association signals in cohorts of extremes is a cost-effective and powerful approach. This replication sample came from another independent unrelated Southern Chinese cohort, with a total of 835 extremely high and extremely low BMD subjects (Supplementary Material, Table S2). Low BMD subjects were arbitrarily defined as those with a BMD T-score of $\leq -1$ or less (equivalent to osteopenia according to WHO definition) at either the spine or hip. High BMD subjects were sex-matched unrelated controls with a BMD T-score of $>-1$ or more (approximately equivalent to 85th percentile of the population). The controls were matched as a group with the cases for age and sex. Detailed inclusion and exclusion criteria and a detailed description of the cohort ascertainment were reported previously (16). This case–control cohort had $>95\%$ power of detecting a significant association with an SNP that has MAF of 0.3 and contributes to 1% variance in BMD. This assumes that the testing SNP is the true causal polymorphism or in complete LD with the causal polymorphism. The power is $>92\%$ if the LD is $>0.8$.

For the third screening, 1268 case–control Japanese subjects with 703 osteoporotic subjects and 565 normal controls were studied. Osteoporosis was defined according to the Japanese Osteoporosis Society as BMD $<70\%$ of young adult mean at either the spine or femur (31). This cutoff is equivalent to the WHO definition of T-score of less than $-2.5$. Controls were age-matched subjects with normal BMD of T-score of greater than $-1$ (cases $74.0 \pm 7.2$ (mean $\pm$ SD) years; controls $73.0 \pm 6.2$ years).

Informed consent was obtained from all subjects, and the study was approved by the ethics committee of the University of Hong Kong and conducted according to the Declaration of Helsinki.

DNA collection, marker selection and genotyping

Genomic DNA extraction from peripheral blood leukocytes was performed using standard phenol/chloroform protocols. In our previous study, the linkage peak was centered on marker D1S196. For the purpose of fine-mapping, the QTL was defined by a drop of 1 in LOD score from the peak, i.e. from 162.5 to 168.5 Mb. According to the NCBI Map Viewer B36.2, 60 genes were located in this region. In the designated region, SNPs were selected from Perlegen genome browser (32) and HAPMAP (33) Chinese population. Gene-based tagging was performed using CLUSTAG (34,35) with $r^2$ threshold of 0.8 and 0.6 for known gene and hypothetical gene/pseudogene, respectively. A total of 380 SNPs were selected as tagging SNPs and force tagging was done for the SNPs located in the coding regions and promoter region.

Genotyping was performed using the SEQUENOM genotyping platform. The allele frequencies used in the study were estimated by direct counting. SNPs with minor allele frequency (MAF) $<0.05$, call rate $<0.9$ and HWE $<0.01$ were excluded from analysis. The physical positions used were from the NCBI B36.2 assembly, database SNP B128.

LD analysis

Pairwise LD was calculated as $r^2$ and $D'$ for all SNP–pair combinations using LDMAX routine in software GOLD (36). Graphical overviews of $r^2$ and $D'$ together with block structure were generated from GOLD software (36) and HAPLOVIEW (37) software, respectively.

Sib-pairs association analyses

Single locus association analyses were carried out using QFAM implemented in PLINK software (38). Total and within-sib-pairs association tests were performed. The total test extracted all association information from the sib-pairs sample controlling for relatedness using a permutation procedure that separated out the between-sib-ships and within-sib-ships components. This is more powerful than a within-sib-ships test but is not robust to population stratification. Therefore, the stringent within-sib-ships test, which is robust to population stratification, was also performed. The QFAM analyses were performed based on the presumption of an additive model. A total of 10 000 permutations were analyzed to correct for relatedness. A nominal $P$-value of 0.05 was considered a significant association. SNPs with $P \leq 0.05$ in both total- and within-association tests were replicated in an independent case–control cohort.

Statistical analysis for case–control replication study

To assess the association of SNPs and BMD status (high versus low), OR and 95% CI were determined using binary logistic regression with or without adjustment for age, sex, height and weight. The additive model of ‘a’ allele was used to evaluate the association. Genotypes AA, Aa and aa were coded additively as 0, 1, 2, whereby ‘A’ represents the major allele and ‘a’ represents the minor allele. SPSS 14.0 for Windows was used for statistical calculations. Meta-analysis (random effects model) was performed to analyze the results from southern Chinese and Japanese (39).

HBDC and MC3T3-E1 cells

Human bone-derived cells from healthy subjects were generated as described previously (40). The isolated adherent HBDCs were harvested for mRNA extraction or fixed with 10% paraformaldehyde for immunohistochemistry study. MC3T3-E1 mouse pre-osteoblast cells were grown in 100 mm diameter tissue culture dish until sub-confluence and passaged with 0.05% trypsin and 0.53 mM EDTA. For
transfection experiments, cells were plated at a density of $2 \times 10^4$ cells cm$^{-2}$. All treatments were initiated after 18 h of incubation, and tissue culture mediums were replenished every 2 days. All cells were maintained at 37°C in a humidified 5% CO$_2$ environment.

**Interfering RNA transfection**

Murine MC3T3-E1 pre-osteoblast cells (clone 4; ATCC) were maintained in α-MEM medium supplemented with 10% fetal bovine serum (40). Oligonucleotides to produce small interfering RNA (RNAi) specific for PBX1 were transfected into MC3T3-E1 cells at a final concentration of 50 nM with Lipofectamine 2000 according to the manufacturer’s instructions (Invitrogen). The PBX1 Stealth™ RNAi negative control was created based on the following sequence: CGAGGCG- GAAGAGACGGAATTTCGGA. RNA with medium GC content was used as negative control. Experiments were performed in duplicate and repeated three times.

**Cell proliferation assay**

Cell proliferation was evaluated using the MTT assay as described previously (41). Briefly, after RNAi transfection, MC3T3-E1 pre-osteoblasts were incubated for 4 days in a 24-well plate. The MTT was added at a final concentration of 0.5 mg/ml for 3 h. Cells were then solubilized with isopropanol containing 0.1% sodium dodecyl sulfate and 0.04 N hydrochloric acid. Absorbance was measured at 570 nm. All experiments were performed in triplicates and repeated three times.

**Semi-quantitative and quantitative real-time PCR**

Total RNA was isolated from HBDCs and MC3T3-E1 cells at specific time points using Tri-reagent™. Real-time PCR was performed using the Taqman™ one-step PCR master mix kit with gene-specific target primers and 3-FAM probes. Primers and PCR conditions are provided in the supplementary information. Each sample was simultaneously quantified using eukaryotic 18S primers and target probes. Amplification was performed in an ABI Prism 7900 HT sequence detector, using standard settings of 40 cycles with an annealing temperature of 60°C. All experiments were performed in triplicates and repeated three times.

**Protein expression studies**

For western blot analysis, whole-cell extracts of MC3T3-E1 were prepared by M-Per lysis buffer (Pierce Biotechnology) containing complete protease inhibitor mix (Roche Applied Science). Equal amounts of protein (10–20 μg) were resolved by 12% SDS–PAGE and electrotransferred to a nitrocellulose membrane. A mouse monoclonal primary antibody for PBX1 (Abnova) with 1/1000 dilution was used. Protein expression was detected by ECL plus (Amersham Biosciences). For immunohistochemical analysis, HBDCs were fixed in ice-cold 10% formalin in PBS for 15 min. Cells were then incubated in a humidified chamber with 1:200 dilution of the primary antibody for PBX1 (Abnova) and col1a1 (Santa Cruz) and 1:1000 Alexa Fluo conjugated secondary antibody. In the negative control, primary antibody was replaced by mouse sera. All experiments were performed in triplicates and repeated three times.

**Von-Kossa staining on mineralized nodules**

For fixation and staining of mineralized bone nodules, cells cultured for 30 days were washed twice with ice-cold PBS and fixed in ice-cold fixative (10% formalin in PBS) for 15 min. Following three washes with de-ionized water, mineralized matrix was detected using Von-Kossa staining by treating fixed cells with 5% silver nitrate for 30 min, followed by washing with 5% sodium carbonate in 10% formalin for 1 min and 5% sodium thiosulfate for 5 min. The reaction was stopped by washing the cells with de-ionized water. The Von-Kossa-stained nodules were viewed and counted under a microscope. All experiments were performed in triplicates and repeated three times.

**SUPPLEMENTARY MATERIAL**

Supplementary Material is available at HMG online.

**ACKNOWLEDGEMENT**

The authors thank K.S. Lau and the staff of the Osteoporosis Centre, Queen Mary Hospital, for assistance in this project.

**Conflict of Interest statement.** None declared.

**FUNDING**

This project is supported by Hong Kong Research Grant Council; KC Wong Education Foundation; The Bone Health Fund, HKU Foundation; Osteoporosis Research Fund and Matching Grant of The University of Hong Kong.

**REFERENCES**


